2021.Feb.17
OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations in Argentina, Brazil, and South Africa
1. Date of occurrence of the event: Feb 17, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. 4.Reciprocal shareholding ratios: No applicable 5. Cause of occurrence: OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, […]
This article is password protected.
To view the content, please enter your password in the field below